An interventional study of High-oleic palm oil in Insulinemic Response, Type 2 Diabetes (Adult Onset) and Hyperglycaemia (Diabetic), sponsored by Ruby Alejandra Villamil. Completed at 1 site in Colombia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Ruby Alejandra Villamil · Not applicable, Interventional, and Basic science
This randomized clinical trial aims to evaluate the effects of refined high-oleic palm oil consumption on cardiovascular risk biomarkers and insulin resistance in healthy adults. Participants will be randomly assigned to two groups to consume either high-oleic palm oil or olive oil for four months in typical domestic preparations.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 52 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →This is the only study on the registry with Ruby Alejandra Villamil as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
o Use of nutritional supplements
Twenty-six participants were assigned to receive refined high oleic palm oil (APAOr) as the exclusive edible cooking oil for household food preparation. Participants received approximately 1.5 L of oil per month and were instructed to use only the assigned oil during the 4-month intervention period.
Other: High-oleic palm oil
Twenty participants were assigned to receive olive oil (AO) as the exclusive edible cooking oil for household food preparation. Participants received approximately 1.5 L of oil per month and were instructed to use only the assigned oil during the 4-month intervention period.
Other: High-oleic palm oil
These findings are expected to confirm the hypothesis that refined high-oleic palm oil offers similar health benefits to extra virgin olive oil, particularly in terms of lipid profile and erythrocyte membrane fatty acid composition. The anticipated results aim to provide robust scientific evidence promoting refined high-oleic palm oil as a healthier alternative for domestic cooking, reinforcing its potential role in cardiovascular health management.
Lipid profile
Plasma levels of cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, and apolipoprotein B
Time frame: From the start of the intervention until the last data point is 4 months. Biochemical laboratory tests are performed every two months, meaning a total of three data points will be collected (initial, intermediate, and final).
Changes in Biomarkers of Glycemic Control and Insulin Resistance
To evaluate the effect of high-oleic palm oil consumption compared to olive oil on fasting glucose, glycated hemoglobin (HbA1c), fasting insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR index), and triglyceride-glucose (TyG) index as indicators of metabolic control and insulin sensitivity.
Time frame: Duration of the intervention: four months, with three laboratory analyses: baseline analysis at 0 month, mid-term analysis at two months, and final analysis at four months.
Liver function
Monitoring variables to ensure that the oils do not alter liver function: Alkaline phosphatase, Aspartate aminotransferase (AST), Alkaline glutamic-pyruvic transaminase (ALT), Gamma-glutamyl transferase (GGT).
Time frame: Intervention duration: four months, with three laboratory tests: initial test at month zero, intermediate test at two months, and final test at four months.
Changes in Plasma Apolipoprotein B Levels
To determine the effect of high-oleic palm oil consumption compared to olive oil on serum concentrations of apolipoprotein B (ApoB), considered a biomarker of atherogenic cardiovascular risk and an indicator of the amount of circulating atherogenic particles.
Time frame: 4 months: Baseline (Month 0), Month 2, and Month 4 of intervention.
Changes in the ApoB/LDL-C Atherogenic Index
To evaluate the effect of high-oleic palm oil consumption compared to olive oil on the ApoB/LDL-C ratio, used as an indirect indicator of the number of atherogenic LDL particles and residual cardiovascular risk.
Time frame: Intervention 4 months: Baseline (Month 0), Month 2, and Month 4 of intervention.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.